A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Interventions

DRUG: Tarlatamab

Sponsor

Amgen